Literature DB >> 17463112

Mortality and mobility after hip fracture in Japan: a ten-year follow-up.

M Tsuboi1, Y Hasegawa, S Suzuki, H Wingstrand, K-G Thorngren.   

Abstract

We studied prospectively the change over ten years in mortality, walking ability and place of residence after a hip fracture in 753 patients in Japan. We compared the deaths observed in these patients with those expected in the general population, matched for age, gender and calender year at the time of fracture. The survival rate decreased dramatically for two years after the event and the mortality risk remained higher for ten years. This risk was approximately double that of the general population, even at ten years after fracture. The risk was higher, and remained so for longer, in younger rather than in older patients. The proportion of patients who were able to walk outdoors alone, with or without an assistive device, was 68% (514) before fracture. This decreased to 56% (340) by one year after and remained stable at approximately 63% (125) until ten years. The proportion of patients living in their own home was 84% (629) before fracture, 81% (491) one year later, and then remained stable at approximately 86% (171) until ten years after the event.

Entities:  

Mesh:

Year:  2007        PMID: 17463112     DOI: 10.1302/0301-620X.89B4.18552

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  43 in total

1.  Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.

Authors:  T Mori; C J Crandall; D A Ganz
Journal:  Osteoporos Int       Date:  2017-02-17       Impact factor: 4.507

2.  Revision surgery occurs frequently after percutaneous fixation of stable femoral neck fractures in elderly patients.

Authors:  Michael S Kain; Andrew J Marcantonio; Richard Iorio
Journal:  Clin Orthop Relat Res       Date:  2014-09-26       Impact factor: 4.176

3.  A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.

Authors:  M Yoshimura; K Moriwaki; S Noto; T Takiguchi
Journal:  Osteoporos Int       Date:  2016-10-14       Impact factor: 4.507

4.  Epidemiology of hip fractures in Okinawa, Japan.

Authors:  Harumi Arakaki; Ichiro Owan; Hirohisa Kudoh; Hidehiro Horizono; Kaoru Arakaki; Yasunari Ikema; Hirotaka Shinjo; Kaori Hayashi; Fuminori Kanaya
Journal:  J Bone Miner Metab       Date:  2010-09-04       Impact factor: 2.626

5.  Mortality after vertebral fracture in Korea: analysis of the National Claim Registry.

Authors:  Y-K Lee; S Jang; S Jang; H J Lee; C Park; Y-C Ha; D-Y Kim
Journal:  Osteoporos Int       Date:  2011-11-23       Impact factor: 4.507

6.  Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up.

Authors:  Ilona Nurmi-Lüthje; Peter Lüthje; Juha-Pekka Kaukonen; Matti Kataja
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

7.  Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.

Authors:  K Moriwaki; S Noto
Journal:  Osteoporos Int       Date:  2016-10-04       Impact factor: 4.507

Review 8.  Fracture mortality: associations with epidemiology and osteoporosis treatment.

Authors:  Sebastian E Sattui; Kenneth G Saag
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

9.  Risk Factor Analysis for 30-Day Mortality After Primary THA in a Single Institution.

Authors:  Fernando Comba; Ignacio Alonso Hidalgo; Martín Buttaro; Francisco Piccaluga
Journal:  HSS J       Date:  2012-06-30

10.  Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.